NCT04290923已完成不适用
Determination of Blood Tumor Cells Using Magnetic Nanoparticles
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 71
- 试验地点
- 1
- 主要终点
- Number of CTC / lymphocytes removed
研究概览
简要总结
Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .
详细描述
Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (EpCAM as marker)can be removed out of the blood with the help of these particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked to test their blood.
Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid tumors in the blood such as lymphoma or leukemia (CD52 as marker).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)
排除标准
- •Inability to understand the language of the center (German)
结局指标
主要结局
Number of CTC / lymphocytes removed
时间窗: 1 day
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
SentiMag Multicentre Trial.Breast CancerSentinel Lymph Node Biopsy (SLNB)Detection of Lymph Node metastases using MRINL-OMON23320This trial is jointly sponsored by King’s College London and Guy’s & St Thomas’ NHS Trust. The trial is being coordinated by the SentiMAG Trials Office, Department of Research Oncology, King’s College London.160
已完成
不适用
Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer PatientsColon CancerNCT00351572Alberta Health services30
已完成
不适用
Sentinel Node Biopsy using Magnetic Nanoparticles for melanomaCancerISRCTN15768185King's College London (UK)160
已完成
不适用
Intracorporeal Nanocomposites and Neurological Disorders in Fulgurates (FulgurnanoF)Neurologic DisorderNCT04380194University Hospital, Clermont-Ferrand27
已完成
不适用
Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With MelanomaMelanomaNCT00588198Memorial Sloan Kettering Cancer Center754